Matthias Ernst
Director, Matthias Ernst Lab
Matthias Ernst Lab Ludwig Center at Melbourne
Ludwig Institute for Cancer Research
Australia
Biography
A PhD graduate from the Swiss Institute of Technology (ETH) in Zurich (Switzerland), I trained initially as a postdoctoral fellow in the Pharmaceutical Industry at Merck Sharp & Dohme (USA) in the area of bone biology. In 1990, I joined the laboratory of Prof Ashley Dunn at the Ludwig Institute for Cancer Research in Melbourne to extend my studies into molecular mechanisms that underpin the growth of cancer cells. In 1996 I was recruited as Deputy Head for the Bone Biology Research Department at Novartis in Switzerland. Following my return to Melbourne in 1998 as Group Leader, Ludwig Melbourne-Parkville Branch, I was appointed Acting Director in 2009. In 2012 I moved to the Walter and Eliza Hall Institute, where I continued to embrace genetic tools and state-of-the-art molecular biology to understand the molecular mechanism that allow the cells of the lining in the stomach and bowel to continuously renew without forming tumours. Recently, my work has identified several critical proteins, which derail this process and allow cells to unabatedly grow when acquiring mutations and to cause cancer of the stomach and the colon. I was appointed inaugural Scientific Director of the newly established Olivia Newton-John Cancer Research Institute in 2014. At the ONJCRI my laboratory team is exploring novel strategies to target these cancer-promoting proteins, to develop new therapeutics for gastrointestinal cancers.
Research Interest
Stomach and the colon cancer, novel protein, cancer mutations
Publications
-
Bollrath, Julia, et al. "gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis." Cancer cell 15.2 (2009): 91-102.
-
Stumhofer, Jason S., et al. "Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10." Nature immunology 8.12 (2007): 1363.
-
Stumhofer, Jason S., et al. "Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system." Nature immunology 7.9 (2006): 937.